LIFESCAPES raises 600M yen for AI-powered BMI stroke rehab device, expands into ASEAN

LIFESCAPES raises 600M yen for AI-powered BMI stroke rehab device, expands into ASEAN

LIFESCAPES, a Japanese neuro-rehabilitation startup, has raised a total of 600 million yen (approximately $4 million) through a third-party allotment of shares. The round includes investors Mitsui Sumitomo Insurance Capital, Mitsubishi UFJ Capital, SBI Investment, Indy Capital, and Fidea Capital. The company has now raised 960 million yen (approximately $6.4 million) cumulatively since its founding in 2018. The funds will accelerate physician-led clinical trials in Japan starting summer 2026 and drive commercial expansion across ASEAN — beginning with Malaysia, where the device has already received regulatory approval and been adopted by the national social security agency PERKESO — as well as Singapore, Indonesia, and Thailand, with a longer-term push into North America.

Why it matters: This is a concentrated application of AI to a hard medical problem — stroke rehabilitation for severe finger paralysis — where the company’s brain-machine interface (BMI) headset measures cortical activity and stimulates paralyzed fingers via a powered orthosis and electrical stimulation, rewiring compensatory neural circuits. The company secured Japanese medical device certification in 2024 and has applied for national health insurance coverage. The ASEAN-first go-to-market strategy is a pragmatic regulatory play: entering markets with faster approval cycles before tackling the U.S. FDA process. The involvement of major Japanese financial institutions (Mitsubishi UFJ, Sumitomo Mitsui) signals growing domestic conviction in AI-integrated medical devices as a category, though the round size remains modest by AI startup standards.

The critical question is whether the insurance reimbursement and clinical trial data can validate the device at scale. The company’s CEO, Professor Junichi Ushiba of Keio University, brings deep domain authority in neuroscience and rehabilitation engineering, which de-risks the science but does not guarantee commercial adoption. The ASEAN expansion is a capital-efficient distribution test: if PERKESO’s adoption leads to measurable outcomes in Malaysia, that data becomes a powerful reference for regulators in higher-value markets. However, the $4 million raise is small even for medical hardware — it will likely require follow-on financing within 12-18 months to fund the U.S. market entry and full-scale manufacturing.

#BrainMachineInterface #StrokeRehab #MedicalDevices #AIHealthcare #JapanDeepTech #ASEANExpansion